Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997176 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
A Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 11
- Study locations
NCT02997176 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 38 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (81% lower). The trial reports 11 study locations across 3 states.
The verdict
NCT02997176, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
Conditions Studied
Interventions
- DRUG Talazoparib
Study Locations (11)
California
- UCLA Hematology/Oncology - Alhambra - Alhambra
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center - Bakersfield
- St. Joseph Heritage Healthcare - Fullerton
- St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare - Fullerton
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology/Oncology - Porter Ranch - Porter Ranch
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
- UCLA Torrance Oncology - Torrance
- UCLA Hematology/Oncology - Santa Clarita - Valencia
Florida
- Orlando Health, Inc. - Orlando
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02997176
The ClinicalTrials.gov registry entry for NCT02997176 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (81% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Talazoparib is the first listed.
NCT02997176 reports 11 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT02997176 about?
NCT02997176 is a clinical study titled "An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)". This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
What is the current status of trial NCT02997176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-09-30. Estimated completion is 2020-02-12.
What conditions does trial NCT02997176 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02997176?
The interventions under investigation include: Talazoparib (DRUG).
Who is sponsoring clinical trial NCT02997176?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997176 being conducted?
This trial has 11 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.